BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37347113)

  • 1. Metabolic reprogramming of clear cell renal cell carcinoma.
    Zhu H; Wang X; Lu S; Ou K
    Front Endocrinol (Lausanne); 2023; 14():1195500. PubMed ID: 37347113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
    Weiss RH
    Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic reprogramming in clear cell renal cell carcinoma.
    Wettersten HI; Aboud OA; Lara PN; Weiss RH
    Nat Rev Nephrol; 2017 Jul; 13(7):410-419. PubMed ID: 28480903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling.
    Shi J; Miao D; Lv Q; Wang K; Wang Q; Liang H; Yang H; Xiong Z; Zhang X
    Cell Death Dis; 2023 Aug; 14(8):560. PubMed ID: 37626050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.
    Tan SK; Hougen HY; Merchan JR; Gonzalgo ML; Welford SM
    Nat Rev Urol; 2023 Jan; 20(1):48-60. PubMed ID: 36192502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
    Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
    Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
    PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
    Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
    Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
    Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics.
    Li W; Wang X; Zhang X; Gong P; Ding D; Wang N; Wang Z
    Lipids Health Dis; 2021 Nov; 20(1):160. PubMed ID: 34774030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF-2α-induced upregulation of CD36 promotes the development of ccRCC.
    Liao M; Li Y; Xiao A; Lu Q; Zeng H; Qin H; Zheng E; Luo X; Chen L; Ruan XZ; Yang P; Chen Y
    Exp Cell Res; 2022 Dec; 421(2):113389. PubMed ID: 36252650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.
    Badoiu SC; Greabu M; Miricescu D; Stanescu-Spinu II; Ilinca R; Balan DG; Balcangiu-Stroescu AE; Mihai DA; Vacaroiu IA; Stefani C; Jinga V
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic reprogramming in renal cancer: Events of a metabolic disease.
    Chakraborty S; Balan M; Sabarwal A; Choueiri TK; Pal S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188559. PubMed ID: 33965513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.
    Lobo NC; Gedye C; Apostoli AJ; Brown KR; Paterson J; Stickle N; Robinette M; Fleshner N; Hamilton RJ; Kulkarni G; Zlotta A; Evans A; Finelli A; Moffat J; Jewett MA; Ailles L
    BMC Cancer; 2016 Jul; 16():485. PubMed ID: 27422173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma.
    Gu YR; Kim J; Na JC; Han WK
    PLoS One; 2022; 17(6):e0269432. PubMed ID: 35671305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma.
    Miess H; Dankworth B; Gouw AM; Rosenfeldt M; Schmitz W; Jiang M; Saunders B; Howell M; Downward J; Felsher DW; Peck B; Schulze A
    Oncogene; 2018 Oct; 37(40):5435-5450. PubMed ID: 29872221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway.
    Miao D; Wang Q; Shi J; Lv Q; Tan D; Zhao C; Xiong Z; Zhang X
    Cancer Commun (Lond); 2023 Apr; 43(4):480-502. PubMed ID: 36860124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and metabolic hallmarks of clear cell renal cell carcinoma.
    Sanchez DJ; Simon MC
    Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):23-31. PubMed ID: 29959988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.